Intuitive Surgical (NASDAQ:ISRG) Posts Earnings Results, Beats Estimates By $0.35 EPS

Intuitive Surgical (NASDAQ:ISRG) posted its earnings results on Tuesday. The medical equipment provider reported $3.00 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.35, FiscalAI reports. The business had revenue of $3.05 billion for the quarter, compared to analysts’ expectations of $2.91 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock traded up $4.82 during trading on Tuesday, reaching $438.00. The company had a trading volume of 2,650,114 shares, compared to its average volume of 2,406,196. Intuitive Surgical has a fifty-two week low of $328.57 and a fifty-two week high of $603.88. The firm’s fifty day moving average is $392.22 and its 200-day moving average is $409.24. The company has a market cap of $154.74 billion, a price-to-earnings ratio of 50.17, a price-to-earnings-growth ratio of 3.22 and a beta of 1.46.

Insiders Place Their Bets

In other news, Director Gary S. Guthart sold 10,000 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $400.00, for a total value of $4,000,000.00. Following the completion of the transaction, the director owned 1,245,679 shares in the company, valued at approximately $498,271,600. This trade represents a 0.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Gary Loeb sold 400 shares of Intuitive Surgical stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the transaction, the executive vice president owned 5,320 shares of the company’s stock, valued at approximately $2,016,280. The trade was a 6.99% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is owned by company insiders.

Trending Headlines about Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Strong robotic-surgery demand: Analysts point to rising procedure volumes, da Vinci 5 adoption and recurring revenue from instruments, accessories and service. Intuitive placed 246 da Vinci 5 systems in the second quarter, compared with 180 a year earlier, while procedures increased approximately 15%. 3 Wall Street Analysts See Intuitive Surgical Hitting $500
• Positive Sentiment: Analyst support: TD Cowen maintained a Buy rating and a $485 price target, citing robust robotic demand and potential upside if forecasts prove conservative. Several analysts see a path toward $500 as the installed base and procedure volumes expand. Intuitive Surgical Analyst Maintains Buy
• Positive Sentiment: Lower-cost adoption strategy: Intuitive plans to extend the useful life of surgical instruments beginning in 2027. Although this may reduce revenue per procedure initially, lower operating costs could make robotic surgery more attractive to hospitals and broaden long-term adoption. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
• Neutral Sentiment: Earnings are the immediate catalyst: Intuitive Surgical is scheduled to report after the market close. Investors are looking for procedure growth, da Vinci 5 placements, operating margins and management’s outlook. Revenue growth is expected to moderate to 15.6% year over year from 22.9% in the comparable quarter last year. Intuitive Surgical Q3 2026 Earnings Preview
• Negative Sentiment: Leasing raises capital-intensity concerns: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it requires Intuitive to fund equipment before realizing its lifetime returns. The stock’s elevated valuation also leaves less room for an earnings or guidance miss. Does Leasing Make Growth More Durable or More Capital Intensive?

Analysts Set New Price Targets

Several research firms recently issued reports on ISRG. UBS Group reaffirmed a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. JPMorgan Chase & Co. cut their price objective on shares of Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating on the stock in a report on Friday, July 17th. TD Cowen reissued a “buy” rating on shares of Intuitive Surgical in a research report on Monday. Evercore set a $430.00 target price on Intuitive Surgical in a research note on Monday, July 6th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Intuitive Surgical in a research report on Friday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $498.83.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.